ORBENIL 2 G

País: Israel

Língua: inglês

Origem: Ministry of Health

Ingredientes ativos:

CLOXACILLIN AS SODIUM

Disponível em:

SALOMON,LEVIN & ELSTEIN LTD

Código ATC:

J01CF02

Forma farmacêutica:

POWDER FOR SOLUTION FOR INJECTION

Composição:

CLOXACILLIN AS SODIUM 2 G/VIAL

Via de administração:

I.M, I.V

Tipo de prescrição:

Required

Fabricado por:

SANDOZ GmbH, AUSTRIA

Grupo terapêutico:

CLOXACILLIN

Área terapêutica:

CLOXACILLIN

Indicações terapêuticas:

For the treatment of infections caused by penicillinase-producing staphylococci. Because of the high incidence of staphylococcal isolates resistant to penicillin G both within and outside the hospiral environment . Orbenil is recommended as initial therapy in patients with suspected staphylococcal infections. Orebenil is also effective in the treatment of other commonly encountered Gram-positive coccal infections.Typical indications include: - respiratory tract infections such as pneumonia and sinusitis - infected wounds and burns - osteomyelitis and septic arthritis - other infections due to staphylococci (including penicillin-resistant strains) such as septicemia endocarditis enterocolitis and urinary tract infections.

Data de autorização:

2011-11-30

Características técnicas

Orbenil Injection , 13. 3. 2011 , RH
"
ע עבקנ הז ןולע טמרופ
"
רשואו קדבנ ונכותו תואירבה דרשמ י
."
רשואמ ןולע
:
ץרמ
2011
.
“This leaflet format has been determined by the Ministry of Health
and the content thereof has been
checked and approved.” Date of approval: March 2011.
אפורל ןולע
Physician's Package Insert
=========================================================================
לינברוא
ORBENIL

---------------------------------------------------------------------------------------------------------------------------
הקרזהל
INJECTION
COMPOSITION
Each vial contains:
_Active Ingredient _
Cloxacillin (as sodium salt) 500 mg or 2 g_ _
_Sodium content: _
_Orbenil 500 mg: 27.5 mg per vial _
_Orbenil 2 g: 110 mg per vial _
MECHANISM OF ACTION
Cloxacillin is an isoxazolyl semisynthetic penicillin which is
markedly resistant to
cleavage by penicillinase. It is a potent inhibitor of the growth of
most penicillinase-
producing staphylococci.
Cloxacillin is effective both by the oral and parenteral routes.
However, in serious
life-threatening staphylococcal infections, initiation of therapy with
Orbenil injection is
recommended.
INDICATIONS
Orbenil is indicated primarily for the treatment of infections caused
by penicillinase-
producing staphylococci. Because of the high incidence of
staphylococcal isolates
resistant to penicillin G, both within and outside the hospital
environment, Orbenil is
recommended as initial therapy in patients with suspected
staphylococcal infections.
Orbenil is also effective in the treatment of other commonly
encountered Gram-
positive coccal infections.
Typical indications include:

respiratory tract infections, such as pneumonia and sinusitis

infected wounds and burns

osteomyelitis and septic arthritis

other infections due to staphylococci (including penicillin-resistant
strains) such
as septicemia, endocarditis, enterocolitis and urinary tract
infections.
CONTRAINDICATIONS
Known hypersensitiv